Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Genitourinary 1

Conditions

Myelodysplastic Syndromes 100Leukemia, Myeloid, Acute 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Myeloproliferative Disorders 40Leukemia, Myelogenous, Chronic, BCR-ABL Positive 37Leukemia, Myelomonocytic, Chronic 32Primary Myelofibrosis 30Lymphoma, Non-Hodgkin 30Polycythemia Vera 19Lymphoma 15Leukemia 15Hematologic Neoplasms 15Leukemia, Biphenotypic, Acute 14Thrombocythemia, Essential 13Histiocytosis, Langerhans-Cell 12Multiple Myeloma 11Hodgkin Disease 11Neuroblastoma 10Neoplasms 10Leukemia, Myeloid, Chronic-Phase 10Leukemia, Lymphocytic, Chronic, B-Cell 10Glioma 10Rhabdoid Tumor 9Medulloblastoma 9Ependymoma 9Anemia, Refractory, with Excess of Blasts 9Wilms Tumor 8Sarcoma 8Rhabdomyosarcoma 8Osteosarcoma 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hypersensitivity × Myeloid × Clear all
NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Cogent Biosciences, Inc.

Phase 2 Active not recruiting
237 enrolled
Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡